The round was closed with an investment from the European Circular Bioeconomy Fund (ECBF) and the two existing investors, Sofinnova Partners and Novo Seeds
This is the 142nd ANDA (including 8 tentative approvals received) out of Eugia Pharma Specialty Group (EPSG) facilities, manufacturing both oral and sterile specialty products.
The JV is funded by Boehringer Ingelheim as lead investor with 30 million EUR and by Evotec and bioMérieux with 5 million EUR each.
This integrated, multi-product facility houses manufacturing suites, analytical testing laboratories and warehousing.
The objective of this Phase 1 study is to determine the safety and tolerability of OLX10212 in patients with advanced AMD at multiple sites in the US.
Companies finalize termination with an agreed-upon settlement fee of $55M to be paid to Akebia
The over-the-counter market has long been an important segment of Glenmark’s portfolio around the world
Safety in these pediatric populations was consistent with the known safety profile across approved adult and pediatric indications1,2
This facility will produce higher efficacy products that enjoy greater acceptance and enhanced profit marginsg
First and only PARP inhibitor to improve invasive disease-free survival in patients
Subscribe To Our Newsletter & Stay Updated
